{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:18:54Z","timestamp":1792009134599,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100004192","name":"The National Science and Technology Development Agency Thailand","doi-asserted-by":"crossref","award":["P-13-003341"],"award-info":[{"award-number":["P-13-003341"]}],"id":[{"id":"10.13039\/501100004192","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The National Vaccine Institute, Thailand","award":["2258.1\/7"],"award-info":[{"award-number":["2258.1\/7"]}]},{"name":"The Thailand Research Fund (TRF) through the Royal Golden Jubilee Ph.D. Program","award":["PHD\/0269\/2552"],"award-info":[{"award-number":["PHD\/0269\/2552"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12985-016-0598-z","type":"journal-article","created":{"date-parts":[[2016,8,18]],"date-time":"2016-08-18T08:45:58Z","timestamp":1471509958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Responses of primary human nasal epithelial cells to EDIII-DENV stimulation: the first step to intranasal dengue vaccination"],"prefix":"10.1186","volume":"13","author":[{"given":"Nattika","family":"Nantachit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panya","family":"Sunintaboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukathida","family":"Ubol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,18]]},"reference":[{"key":"598_CR1","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nri3916","volume":"15","author":"G Screaton","year":"2015","unstructured":"Screaton G, Mongkolsapaya J, Yacoub S, Roberts C. New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol. 2015;15:745\u201359.","journal-title":"Nat Rev Immunol"},{"key":"598_CR2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1517\/17425247.2015.1044435","volume":"12","author":"Y Jia","year":"2015","unstructured":"Jia Y, Krishnan L, Omri A. Nasal and pulmonary vaccine delivery using particulate carriers. Expert Opin Drug Deliv. 2015;12:993\u20131008.","journal-title":"Expert Opin Drug Deliv"},{"key":"598_CR3","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1016\/j.vaccine.2015.07.022","volume":"33","author":"R Pabst","year":"2015","unstructured":"Pabst R. Mucosal vaccination by the intranasal route. Nose-associated lymphoid tissue (NALT)-Structure, function and species differences. Vaccine. 2015;33:4406\u201313.","journal-title":"Vaccine"},{"key":"598_CR4","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.4161\/hv.36174","volume":"10","author":"M Wang","year":"2014","unstructured":"Wang M, Gao Z, Zhang Z, Pan L, Zhang Y. Roles of M cells in infection and mucosal vaccines. Hum Vaccin Immunother. 2014;10:3544\u201351.","journal-title":"Hum Vaccin Immunother"},{"key":"598_CR5","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2174\/0929866521666140807114240","volume":"21","author":"A Patel","year":"2014","unstructured":"Patel A, Patel M, Yang X, Mitra AK. Recent advances in protein and peptide drug delivery: a special emphasis on polymeric nanoparticles. Protein Pept Lett. 2014;21:1102\u201320.","journal-title":"Protein Pept Lett"},{"key":"598_CR6","doi-asserted-by":"crossref","first-page":"797","DOI":"10.4161\/hv.27449","volume":"10","author":"A Smith","year":"2014","unstructured":"Smith A, Perelman M, Hinchcliffe M. Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines. Hum Vaccin Immunother. 2014;10:797\u2013807.","journal-title":"Hum Vaccin Immunother"},{"key":"598_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jiec.2015.10.028","volume":"33","author":"C Choi","year":"2016","unstructured":"Choi C, Nam J-P, Nah J-W. Application of chitosan and chitosan derivatives as biomaterials. J Ind Eng Chem. 2016;33:1\u201310.","journal-title":"J Ind Eng Chem"},{"key":"598_CR8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2009.08.018","volume":"140","author":"N Hagenaars","year":"2009","unstructured":"Hagenaars N, Verheul RJ, Mooren I, de Jong PH, Mastrobattista E, Glansbeek HL, et al. Relationship between structure and adjuvanticity of N, N, N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine. J Control Release. 2009;140:126\u201333.","journal-title":"J Control Release"},{"key":"598_CR9","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1016\/j.vaccine.2012.06.035","volume":"30","author":"M Tafaghodi","year":"2012","unstructured":"Tafaghodi M, Saluja V, Kersten GF, Kraan H, Slutter B, Amorij JP, et al. Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: impact of formulation on physicochemical and immunological characteristics. Vaccine. 2012;30:5341\u20138.","journal-title":"Vaccine"},{"key":"598_CR10","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/jmv.24253","volume":"87","author":"Q Liu","year":"2015","unstructured":"Liu Q, Zheng X, Zhang C, Shao X, Zhang X, Zhang Q, et al. Conjugating influenza a (H1N1) antigen to n-trimethylaminoethylmethacrylate chitosan nanoparticles improves the immunogenicity of the antigen after nasal administration. J Med Virol. 2015;87:1807\u201315.","journal-title":"J Med Virol"},{"key":"598_CR11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1021\/acs.molpharmaceut.5b00707","volume":"13","author":"F Lebre","year":"2016","unstructured":"Lebre F, Borchard G, Faneca H. Pedroso de Lima MC, Borges O. Intranasal administration of novel chitosan nanoparticle\/DNA complexes induces antibody response to Hepatitis B surface antigen in mice. Mol Pharm. 2016;13:472\u201382.","journal-title":"Mol Pharm"},{"key":"598_CR12","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3109\/02652048.2015.1073393","volume":"32","author":"E Cevher","year":"2015","unstructured":"Cevher E, Salomon SK, Somavarapu S, Brocchini S, Alpar HO. Development of chitosan\u2013pullulan composite nanoparticles for nasal delivery of vaccines: in vivo studies. J Microencapsul. 2015;32:769\u201383.","journal-title":"J Microencapsul"},{"key":"598_CR13","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s11095-009-9845-y","volume":"26","author":"N Hagenaars","year":"2009","unstructured":"Hagenaars N, Mastrobattista E, Verheul RJ, Mooren I, Glansbeek HL, Heldens JG, et al. Physicochemical and immunological characterization of N, N, N-trimethyl chitosan-coated whole inactivated influenza virus vaccine for intranasal administration. Pharm Res. 2009;26:1353\u201364.","journal-title":"Pharm Res"},{"key":"598_CR14","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.carbpol.2012.04.056","volume":"89","author":"R Subbiah","year":"2012","unstructured":"Subbiah R, Ramalingam P, Ramasundaram S, Kim do Y, Park K, Ramasamy MK, et al. N, N, N-Trimethyl chitosan nanoparticles for controlled intranasal delivery of HBV surface antigen. Carbohydr Polym. 2012;89:1289\u201397.","journal-title":"Carbohydr Polym"},{"key":"598_CR15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1586\/erv.09.139","volume":"9","author":"MG Guzman","year":"2010","unstructured":"Guzman MG, Hermida L, Bernardo L, Ramirez R, Guillen G. Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines. 2010;9:137\u201347.","journal-title":"Expert Rev Vaccines"},{"key":"598_CR16","doi-asserted-by":"crossref","first-page":"7769","DOI":"10.1128\/JVI.75.16.7769-7773.2001","volume":"75","author":"WD Crill","year":"2001","unstructured":"Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol. 2001;75:7769\u201373.","journal-title":"J Virol"},{"key":"598_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.micinf.2006.09.009","volume":"9","author":"JF Chin","year":"2007","unstructured":"Chin JF, Chu JJ, Ng ML. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect. 2007;9:1\u20136.","journal-title":"Microbes Infect"},{"key":"598_CR18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12896-016-0243-3","volume":"16","author":"N Kaushik","year":"2016","unstructured":"Kaushik N, Rohila D, Arora U, Raut R, Lamminmaki U, Khanna N, et al. Casamino acids facilitate the secretion of recombinant dengue virus serotype-3 envelope domain III in Pichia pastoris. BMC Biotechnol. 2016;16:12.","journal-title":"BMC Biotechnol"},{"key":"598_CR19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jviromet.2010.03.002","volume":"167","author":"G Batra","year":"2010","unstructured":"Batra G, Raut R, Dahiya S, Kamran N, Swaminathan S, Khanna N. Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies. J Virol Methods. 2010;167:10\u20136.","journal-title":"J Virol Methods"},{"key":"598_CR20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijpharm.2006.11.027","volume":"336","author":"F Chen","year":"2007","unstructured":"Chen F, Zhang ZR, Huang Y. Evaluation and modification of N-trimethyl chitosan chloride nanoparticles as protein carriers. Int J Pharm. 2007;336:166\u201373.","journal-title":"Int J Pharm"},{"key":"598_CR21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003958","volume":"9","author":"T Hunsawong","year":"2015","unstructured":"Hunsawong T, Sunintaboon P, Warit S, Thaisomboonsuk B, Jarman RG, Yoon IK, et al. Immunogenic properties of a BCG adjuvanted chitosan nanoparticle-based dengue vaccine in human dendritic cells. PLoS Negl Trop Dis. 2015;9, e0003958.","journal-title":"PLoS Negl Trop Dis"},{"key":"598_CR22","volume":"10","author":"Y Gao","year":"2015","unstructured":"Gao Y, Su Q, Yi Y, Jia Z, Wang H, Lu X, et al. Enhanced mucosal immune responses induced by a combined candidate mucosal vaccine based on Hepatitis A virus and Hepatitis E virus structural proteins linked to tuftsin. PLoS One. 2015;10, e0123400.","journal-title":"PLoS One"},{"key":"598_CR23","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01005-15","volume":"6","author":"SK Khattar","year":"2015","unstructured":"Khattar SK, Manoharan V, Bhattarai B, LaBranche CC, Montefiori DC, Samal SK. Mucosal immunization with newcastle disease virus vector coexpressing HIV-1 Env and Gag proteins elicits potent serum, mucosal, and cellular immune responses that protect against vaccinia virus Env and Gag challenges. MBio. 2015;6, e01005.","journal-title":"MBio"},{"key":"598_CR24","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12985-015-0387-0","volume":"12","author":"EH Kim","year":"2015","unstructured":"Kim EH, Choi YK, Kim CJ, Sung MH, Poo H. Intranasal administration of poly-gamma glutamate induced antiviral activity and protective immune responses against H1N1 influenza A virus infection. Virol J. 2015;12:160.","journal-title":"Virol J"},{"key":"598_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2014.12.009","volume":"115","author":"YN Lee","year":"2015","unstructured":"Lee YN, Hwang HS, Kim MC, Lee YT, Lee JS, Moore ML, et al. Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease. Antiviral Res. 2015;115:1\u20138.","journal-title":"Antiviral Res"},{"key":"598_CR26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1128\/CVI.00778-14","volume":"22","author":"T Qin","year":"2015","unstructured":"Qin T, Yin Y, Huang L, Yu Q, Yang Q. H9N2 influenza whole inactivated virus combined with polyethyleneimine strongly enhances mucosal and systemic immunity after intranasal immunization in mice. Clin Vaccine Immunol. 2015;22:421\u20139.","journal-title":"Clin Vaccine Immunol"},{"key":"598_CR27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/sji.12288","volume":"81","author":"M Trondsen","year":"2015","unstructured":"Trondsen M, Aqrawi LA, Zhou F, Pedersen G, Trieu MC, Zhou P, et al. Induction of local secretory IgA and multifunctional CD4(+) T-helper cells following intranasal immunization with a H5N1 whole inactivated influenza virus vaccine in BALB\/c mice. Scand J Immunol. 2015;81:305\u201317.","journal-title":"Scand J Immunol"},{"key":"598_CR28","volume":"10","author":"X Yang","year":"2015","unstructured":"Yang X, Zhao J, Wang C, Duan Y, Zhao Z, Chen R, et al. Immunization with a live attenuated H7N9 influenza vaccine protects mice against lethal challenge. PLoS One. 2015;10, e0123659.","journal-title":"PLoS One"},{"key":"598_CR29","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.vaccine.2007.12.047","volume":"26","author":"AC Sim","year":"2008","unstructured":"Sim AC, Lin W, Tan GK, Sim MS, Chow VT, Alonso S. Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen. Vaccine. 2008;26:1145\u201354.","journal-title":"Vaccine"},{"key":"598_CR30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ijpharm.2005.03.035","volume":"298","author":"C Foged","year":"2005","unstructured":"Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm. 2005;298:315\u201322.","journal-title":"Int J Pharm"},{"key":"598_CR31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.coviro.2015.02.007","volume":"12","author":"C Lupfer","year":"2015","unstructured":"Lupfer C, Malik A, Kanneganti TD. Inflammasome control of viral infection. Curr Opin Virol. 2015;12:38\u201346.","journal-title":"Curr Opin Virol"},{"key":"598_CR32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000353902","volume":"57","author":"JC Hernandez","year":"2014","unstructured":"Hernandez JC, Latz E, Urcuqui-Inchima S. HIV-1 induces the first signal to activate the NLRP3 inflammasome in monocyte-derived macrophages. Intervirology. 2014;57:36\u201342.","journal-title":"Intervirology"},{"key":"598_CR33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nri3446","volume":"13","author":"LA O'Neill","year":"2013","unstructured":"O'Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol. 2013;13:453\u201360.","journal-title":"Nat Rev Immunol"},{"key":"598_CR34","doi-asserted-by":"crossref","first-page":"304ra142","DOI":"10.1126\/scitranslmed.aaa3863","volume":"7","author":"N Modhiran","year":"2015","unstructured":"Modhiran N, Watterson D, Muller DA, Panetta AK, Sester DP, Liu L, et al. Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity. Sci Transl Med. 2015;7:304ra142.","journal-title":"Sci Transl Med"},{"key":"598_CR35","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1002\/smll.201300481","volume":"9","author":"M Yang","year":"2013","unstructured":"Yang M, Flavin K, Kopf I, Radics G, Hearnden CH, McManus GJ, et al. Functionalization of carbon nanoparticles modulates inflammatory cell recruitment and NLRP3 inflammasome activation. Small. 2013;9:4194\u2013206.","journal-title":"Small"},{"key":"598_CR36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0378-5173(98)00367-6","volume":"178","author":"RJ Soane","year":"1999","unstructured":"Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm. 1999;178:55\u201365.","journal-title":"Int J Pharm"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-016-0598-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T16:56:51Z","timestamp":1498323411000},"score":1,"resource":{"primary":{"URL":"http:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-016-0598-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,18]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["598"],"URL":"https:\/\/doi.org\/10.1186\/s12985-016-0598-z","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,18]]},"article-number":"142"}}